Small molecule · Inhibitor · developed by Lipocine
d-Alpha-Tocopherol is a naturally occurring form of vitamin E with antioxidant activity as a peroxyl radical scavenger. It also noncompetitively inhibits cyclooxygenase activity and suppresses VEGF gene transcription. It is studied in nonalcoholic steatohepatitis, where it is given together with testosterone undecanoate in the LPCN 1144 formulation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04134091 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | Completed | LPCN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Nonalcoholic Steatohepatitis (NASH)
Updated Oct 18, 2026. Something wrong or missing? Report it on the LPCN page.
See LPCN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LPCN catalysts and pipeline →